Hepatitis

Accelerated fibrosis in women with a hepatitis C/HIV co-infection begins as early as pre-menopausal years.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

A look at the top stories in pharmacy last week.

Patients with psychological and substance use problems are less likely to stay engaged in hepatitis C care.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

The risk of developing liver cancer is similar with direct-acting antiviral drugs or interferon therapy for hepatitis C virus.

Treatments for hepatitis C, hemophilia, and cholesterol among specialty drugs approved for new indications this year.

West Virginia University program seeks to combat the spread of infectious diseases via injection drug use.

Baby boomer hepatitis C virus screening rates spiked when a prompt in their electronic health records reminded a primary care provider to recommend testing.

Patients who have received a transplant and are non-adherent to their medication regimens are more likely to experience graft failure and higher health care costs.

Hepatitis C elimination program screens more than 45K individuals in first 2 years of launch.

Triple drug regimen effectively cured patients with hepatitis C virus after they failed to respond to a combination of two oral direct-acting antivirals.

Elderly patients with hepatitis C are typically difficult to treat due to poor tolerability and suboptimal response to interferon-based regimens.

Top news of the week from Specialty Pharmacy Times.

Issues surrounding patents for curative drugs allow pharmaceutical companies to establish a market monopoly and charge astronomical prices.

An estimated 2.7 million Americans have hepatitis C, too many for specialists to be the sole provider of anti-HCV therapy.

Heplisav-B aims to boost a patient’s own immune response to fight off HBV.

Maviret is an 8-week treatment that combines 2 distinct antiviral agents.

Top news of the week from Specialty Pharmacy Times.

Officials with the FDA have announced the approval of glecaprevir and pibrentasvir (Mavyret, AbbVie Inc) for hepatitis C.

Mavyret approved for chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis.

Combination therapy cuts standard HCV treatment regimen from 12 weeks to 8 weeks.

HEV is reemerging as a zoonotic virus, with individuals becoming infected via pigs and pork products.

The label has been updated to include data from adults co-infected with hepatitis C virus and HIV-1.

Top articles of the week from Specialty Pharmacy Times.

Prequalification will allow countries to access generic sofosbuvir and an HIV self-test.

Approximately 325 million individuals are living with hepatitis worldwide.

There are now 8 FDA approved medications for HCV treatment, all of which bypass the use of interferon.